OSCR.NYSEOscar Health, INC
10-Q: Oscar Health Reports Strong Q1 2025 Results, Driven by Membership Growth
Sentiment:
Quarterly Report
Oscar Health's Q1 2025 results show significant revenue growth and profitability, driven by a substantial increase in membership.
Better than expectedThe company reported a net income of $275.27 million compared to $177.482 million in the same period last year.Total revenue increased by 43% to $3.046 billion compared to Q1 2024.The SG&A Expense Ratio improved to 15.8%, reflecting fixed cost leverage and variable cost efficiencies.
Summary
- Oscar Health, Inc. reported its Q1 2025 financial results, showing a net income attributable to Oscar Health, Inc. of $275.27 million.
- Total revenue for the quarter was $3.046 billion, compared to $2.142 billion in Q1 2024.
- The company's effectuated membership reached approximately 2.0 million as of March 31, 2025, up from 1.448 million in the prior year.
- The Medical Loss Ratio (MLR) was 75.4%, compared to 74.2% in the same period last year.
- Selling, General, and Administrative (SG&A) expenses were $482.759 million, representing 15.8% of total revenue, an improvement from 18.4% in Q1 2024.
- The company's investment income increased to $46.112 million from $42.989 million year-over-year.
- The company is closely monitoring regulatory developments, including potential changes to the ACA and the impact of Medicaid redeterminations.
- The company's convertible senior notes are now convertible at the option of the holder.
Sentiment
Score: 8
Explanation: The document presents a positive outlook with strong financial results and membership growth. While there are risks and challenges, the overall tone is optimistic.
Positives
- Significant revenue growth driven by increased membership.
- Improved SG&A Expense Ratio indicates better cost management.
- The company is profitable with a net income of $275.27 million.
- Investment income increased due to a larger asset base.
- The company's convertible senior notes are now convertible at the option of the holder.
Negatives
- The Medical Loss Ratio (MLR) increased slightly to 75.4%, driven by unfavorable prior period development primarily due to the 2024 Risk Adjustment payable, partially offset by favorable claims runout and a cost sharing reduction (CSR) recovery accrual.
Risks
- Regulatory changes, including potential changes to the ACA and Medicaid redeterminations, could impact membership and market stability.
- The company's risk transfer estimates are subject to a high degree of estimation and variability.
- Inability to accurately estimate medical expenses or effectively manage medical costs could negatively affect financial results.
- The company operates in a highly competitive environment.
- The potential impact of tariffs on pharmaceutical products and medical devices could increase medical expenses.
Future Outlook
The company is focused on managing medical costs, expanding its member base, and monitoring regulatory developments. They anticipate lower SEP membership growth throughout 2025.
Management Comments
- We regularly review our Total Revenue, Medical Loss Ratio (MLR), Selling, General and Administrative Expense Ratio (SG&A Expense Ratio), Earnings from Operations, and Net Income attributable to Oscar Health Inc. to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions.
- We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.
Industry Context
The report highlights the impact of regulatory changes, such as potential changes to the ACA and Medicaid redeterminations, which are affecting the health insurance market. The company is also navigating a competitive landscape with larger, more established players.
Comparison to Industry Standards
- The report does not provide specific comparisons to industry standards or competitors.
- However, it mentions that some competitors have greater financial resources and offer a broader scope of products.
- The company's ability to manage its MLR and SG&A Expense Ratio will be critical to its long-term success in the competitive health insurance market.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| EVP and President of Oscar Insurance | N/A | Janet Liang | February 24, 2025 | New hire |
Legal Proceedings
- A securities class action lawsuit against the Company, certain of its directors and officers, and the underwriters that participated in the Companys initial public offering (IPO) was dismissed with prejudice on April 22, 2025.
Related Party Transactions
- In February 2022, the Company issued the 2031 Notes to funds affiliated with, among others, Thrive Capital.
Stakeholder Impact
- Shareholders will likely react positively to the strong financial results and membership growth.
- Employees may benefit from the company's improved financial performance and growth prospects.
- Members may experience improved services and coverage as the company continues to invest in its technology platform.
Next Steps
- The company will continue to provide transition and run-off services for the Cigna+Oscar Small Group plan through December 31, 2026.
- The company will reevaluate its risk adjustment transfer estimates as new information and market data becomes available.
- The company will monitor regulatory developments and adapt its strategies accordingly.
Key Dates
| Date | Description |
|---|---|
| 2012 | Oscar Health was founded. |
| February 21, 2021 | Original date of the senior secured credit agreement. |
| March 5, 2021 | Date of the Twelfth Amended and Restated Investors' Rights Agreement. |
| January 27, 2022 | First Amendment to Credit Agreement. |
| February 3, 2022 | Date of issuance of $305.0 million in aggregate principal amount of convertible senior notes due 2031. |
| May 12, 2022 | Securities class action lawsuit commenced against the Company. |
| July 21, 2023 | Second Amendment to Credit Agreement. |
| April 1, 2023 | Medicaid redeterminations began. |
| March 31, 2023 | Special Enrollment Period (SEP) began to facilitate enrollment in the ACA. |
| December 28, 2023 | Company entered into a third amendment to its senior secured credit agreement. |
| December 31, 2024 | Expiration of the initial term of the Cigna+Oscar Small Group arrangement. |
| November 30, 2024 | Special Enrollment Period (SEP) ended to facilitate enrollment in the ACA. |
| February 7, 2025 | Alessandrea Quane, the Company's former Chief Insurance Officer, terminated the Rule 10b5-1 trading arrangement. |
| February 24, 2025 | Effective date of Janet Liang's employment as EVP and President of Oscar Insurance. |
| March 6, 2025 | The Court granted the motion to dismiss the amended complaint without prejudice and granted leave to file a second amended complaint. |
| March 10, 2025 | CMS issued proposed rules on March 10, 2025 that would create more stringent procedures to confirm member eligibility for APTCs. |
| April 22, 2025 | The Court dismissed the case with prejudice. |
| April 30, 2025 | Shares Outstanding as of April 30, 2025 (in thousands): Class A Common Stock, par value $0.00001 per share 219,163, Class B Common Stock, par value $0.00001 per share 35,514 |
| June 30, 2027 | Initial Purchasers of the 2031 Notes have the right to require the Company to repurchase all of their Notes for cash. |
| December 28, 2025 | The Revolving Credit Facility is available for the Company to borrow under until December 28, 2025. |
| December 31, 2025 | The enhanced APTCs will expire at the end of 2025 if Congress does not take action. |
| December 31, 2026 | The Company may redeem all, but not less than all, of the 2031 Notes, at the Company's option, on or after December 31, 2026. |
| August 31, 2031 | The 2031 Notes are convertible into the Company's Class A common stock on or after August 31, 2031. |
| December 31, 2031 | The 2031 Notes will mature on December 31, 2031, subject to earlier repurchase, redemption, or conversion. |
Keywords
Oscar Health, financial results, Q1 2025, membership growth, revenue, profitability, healthcare, insurance, Medical Loss Ratio, SG&A Expense Ratio, ACA, risk adjustment, convertible notes
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.